Cadrenal Therapeutics CVKD
NASDAQ CVKD
$1.39 -0.05 (-3.47%)
As of: Nov 11, 2026 · 11:03 AM EST

Cadrenal Therapeutics (CVKD) Return on Equity [ROE] (2023 - 2026)

Updated

Cadrenal Therapeutics (CVKD) posted Return on Equity [ROE] of -400.44% for Q2 2026, down 205.83 percentage points from -194.61% a year earlier.

Analysis

Cadrenal Therapeutics (CVKD) Return on Equity [ROE] (2023 - 2026) Analysis & Trends

For FY2023, Cadrenal Therapeutics' Return on Equity [ROE] came in at -689.68%.

  • The Q2 2026 figure stands as the lowest quarterly Return on Equity [ROE] in data going back to Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Cadrenal Therapeutics 557,746.58 -12.06 Mn - -392.06%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -392.06%
Mar 31, 2026 -524.20%
Dec 31, 2025 -483.67%
Sep 30, 2025 -409.04%
Jun 30, 2025 -270.99%
Mar 31, 2025 -189.39%
Dec 31, 2024 -196.30%
Sep 30, 2024 -205.50%
Jun 30, 2024 -122.48%
Mar 31, 2024 -69.82%
Dec 31, 2023 -89.88%
Sep 30, 2023 -123.09%
Jun 30, 2023 -201.27%
API Access

Cadrenal Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=CVKD&period=max&api_key=YOUR_API_KEY